Table 2

 Number of discrete studies by type of cancer

Type of cancerStudies with CRP as 
 >the main aim, n (%)Studies with other 
 >main aim, n (%)
CRP, C reactive protein.
Lung cancer5 (9.3)6 (16.7)
Colorectal cancer6 (11.1)5 (13.9)
Multiple myeloma3 (5.6)4 (11.1)
Gastrointestinal cancer4 (7.4)2 (5.6)
Ovarian cancer2 (3.7)2 (5.6)
Prostate cancer3 (5.6)2 (5.6)
Pancreatic cancer2 (3.7)2 (5.6)
Hepatocellular carcinoma4 (7.4)
Lymphatic cancers3 (5.6)1 (2.8)
Breast cancer2 (3.7)1 (2.8)
Cervical cancer2 (3.7)
Testicular cancer1 (1.9)1 (2.8)
Head and neck squamous cell carcinoma2 (5.6)
Glioma1 (1.9)
Leukaemia1 (1.9)
Bronchial carcinoma1 (1.9)
Kaposi’s sarcoma1 (2.8)
Brain cancer1 (2.8)
Renal cell carcinoma1 (2.8)
Oesophageal cancer1 (1.9)–—
Biliary tract1 (1.9)
Various cancers grouped together in analysis9 (16.7)3 (8.3)
Various cancers analysed as separate types3 (5.6)2 (5.6)
Total54 (100)36 (100)